AZN.UK

12,598

+1.32%↑

GSK

1,620

-1.7%↓

STJ

1,293

+0.58%↑

HIK

1,841

+0.82%↑

AZN.UK

12,598

+1.32%↑

GSK

1,620

-1.7%↓

STJ

1,293

+0.58%↑

HIK

1,841

+0.82%↑

AZN.UK

12,598

+1.32%↑

GSK

1,620

-1.7%↓

STJ

1,293

+0.58%↑

HIK

1,841

+0.82%↑

AZN.UK

12,598

+1.32%↑

GSK

1,620

-1.7%↓

STJ

1,293

+0.58%↑

HIK

1,841

+0.82%↑

AZN.UK

12,598

+1.32%↑

GSK

1,620

-1.7%↓

STJ

1,293

+0.58%↑

HIK

1,841

+0.82%↑

Search

Haleon PLC

Uždarymo kaina

SektoriusSveikatos priežiūra

331.8 0.58

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

325.1

Max

332.9

Pagrindiniai rodikliai

By Trading Economics

Pajamos

172M

403M

Pardavimai

-19M

2.7B

P/E

Sektoriaus vid.

19.388

35.739

Dividendų pajamingumas

2.06

Pelno marža

14.708

Darbuotojai

24,561

EBITDA

17M

697M

Rekomendacijos

By TipRanks

Rekomendacijos

Pirkti

12 mėnesių prognozė

+27.38% upside

Dividendai

By Dow Jones

Dividendų pajamingumas

Sektoriaus vid.

2.06%

3.08%

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-5.8B

29B

Ankstesnė atidarymo kaina

331.22

Ankstesnė uždarymo kaina

331.8

Naujienos nuotaikos

By Acuity

50%

50%

149 / 371 reitingas Healthcare

Haleon PLC Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-07-31 08:02; UTC

Uždarbis
Pagrindinės rinkos jėgos

Haleon Shares Fall on Cut to Organic Revenue Guidance

2025-07-31 07:03; UTC

Uždarbis

Haleon Raises 2025 Profit Guidance, Cuts Revenue Growth Targets

2025-04-15 09:37; UTC

Įsigijimai, susijungimai, perėmimai

Haleon Acquires Chinese JV in $264 Million Deal

2025-07-31 06:14; UTC

Uždarbis

Analysts Saw Haleon 1H Adjusted PBT at GBP1.10B

2025-07-31 06:14; UTC

Uždarbis

Haleon 1H Adjusted PBT GBP1.11B

2025-07-31 06:12; UTC

Uždarbis

Haleon Declares 1H Dividend of 2.2 Pence

2025-07-31 06:11; UTC

Uždarbis

Haleon: Targets High-single Digit Adjusted Operating Profit Growth from 2026

2025-07-31 06:10; UTC

Uždarbis

Haleon: From 2026 Targets 4%-6% Annual Organic Revenue Growth

2025-07-31 06:09; UTC

Uždarbis

Haleon: Targets High-Single Digit Organic Operating Profit Growth in 2025

2025-07-31 06:08; UTC

Uždarbis

Haleon: Lowers Guidance to 2025 Organic Revenue at Around 3.5%

2025-07-31 06:05; UTC

Uždarbis

Haleon 1H Free Cash Flow GBP734M

2025-07-31 06:05; UTC

Uždarbis

Haleon 1H Adjusted Operating Profit Margin 22.7%

2025-07-31 06:05; UTC

Uždarbis

Haleon 1H Adjusted Operating Profit GBP1.24B

2025-07-31 06:02; UTC

Uždarbis

Analysts Saw Haleon 1H Rev GBP5.50B

2025-07-31 06:02; UTC

Uždarbis

Haleon 1H Rev GBP5.48B

2025-06-27 09:05; UTC

Įsigijimai, susijungimai, perėmimai

Haleon: TSKF Is Now a Wholly Owned Unit of Haleon

2025-06-27 09:05; UTC

Įsigijimai, susijungimai, perėmimai

Haleon: Acquired Remaining Stake for GBP0.2 Billion

2025-06-27 09:03; UTC

Įsigijimai, susijungimai, perėmimai

Haleon: Bought Remaining 12% Equity Interest in Tianjin TSKF Pharmaceutical

2025-06-27 09:01; UTC

Įsigijimai, susijungimai, perėmimai

Haleon Completed Acquisition of Remaining 12% in China JV

2025-05-30 13:47; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

Consumer Health Sector Has Room for More Dealmaking -- Market Talk

2025-04-30 08:33; UTC

Rinkos pokalbiai
Uždarbis

Haleon's Vitamins & Supplements Business Weakness in Focus Among Results -- Market Talk

2025-04-30 06:09; UTC

Uždarbis

Haleon Expects Macroeconomic Environment to Remain Challenging, Uncertain

2025-04-30 06:09; UTC

Uždarbis

Haleon Continues to Deliver Against Capital Allocation Priorities

2025-04-30 06:08; UTC

Uždarbis

Analysts Saw Haleon 1Q Organic Revenue Growth at 5.1%

2025-04-30 06:03; UTC

Uždarbis

Haleon Sees 2025 Adjusted Operating Profit Growth Ahead of Revenue Growth

2025-04-30 06:03; UTC

Uždarbis

Haleon Sees 2025 Organic Revenue Growth of 4%-6%

2025-04-30 06:03; UTC

Uždarbis

Haleon Backs 2025 View

2025-04-30 06:03; UTC

Uždarbis

Haleon 1Q Rev GBP2.85B

2025-04-30 06:01; UTC

Uždarbis

Haleon 1Q Organic Revenue Growth up 3.5%

2025-04-29 19:47; UTC

Uždarbis

Pfizer Shares Rise on CEO's Optimism on Threatened Drug Tariffs -- Barrons.com

Akcijų palyginimas

Kainos pokytis

Haleon PLC Prognozė

Kainos tikslas

By TipRanks

27.38% į viršų

12 mėnesių prognozė

Vidutinis 424.29 GBX  27.38%

Aukščiausias 500 GBX

Žemiausias 370 GBX

Remiantis 8 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Haleon PLC kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

8 ratings

5

Pirkti

2

Laikyti

1

Parduoti

Rinkos nuotaikos

By Acuity

149 / 371 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Neutral

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Aukščiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Haleon PLC

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands. It also offers various over-the-counter products comprising nasal drops, and cold, flu, and allergy relief products under Otrivine, Theraflu, and Flonase brands for respiratory issues; anti-inflammatory and pain relief products under Voltaren, Panadol, and Advil brands; and antacids and antihistamine products under TUMS, ENO, and Fenistil brands for digestive health and other issues. The company was formerly known as DRVW 2022 plc and changed its name to Haleon plc in February 2022. Haleon plc was founded in 1715 and is headquartered in Weybridge, the United Kingdom.
help-icon Live chat